BioSpace News Archive

Portage Biotech Inc. (NASDAQ: PRTG), today announced that it has entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health, and Stimunity, S.A.S, an affiliate of Portage with experience in the preclinical development of stimulator of interferon genes (STING) agonists for cancer immunotherapy and infectious diseases.

Vaccinex, Inc. announced that it has been selected for poster presentation related to its ActivMAb technology platform during the upcoming 18th Annual PEGS Boston Conference & Expo, taking place from May 2nd to May 6th via in person and virtual attendance.

BioVie Inc. announced the participation of its management team in a fireside chat and one-on-one meetings at the B. Riley Securities’ Neuro & Ophthalmology Conference, to be held virtually April 27-28, 2022.

LabVantage Solutions, Inc. announced the introduction of LabVantage Forensic NavigatorTM, an industry expert-built informatics platform designed to seamlessly manage the vast amounts of forensic evidence and data used throughout the entire criminal justice life cycle.

RayzeBio, Inc. appointed Angie You, Ph.D., to its board of directors.

iECURE today announced the appointment of George A. Diaz, M.D. Ph.D., as VP, Therapeutic Area Lead for Urea Cycle Disorders (UCDs).

Quoin Pharmaceuticals Ltd. today announced that it has received U.S. Food and Drug Administration (FDA) clearance to initiate clinical testing for its Investigational New Drug (IND) application for QRX003, the Company’s investigational product for Netherton Syndrome (NS).

R2 Technologies Inc. (“R2"), the world leader in CryoAesthetic™ medical devices, today announced that they have shipped 100 GLACIAL® devices to customers globally.

Progenity, Inc., a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations.

Black Diamond Therapeutics, Inc. today announced that it is realigning its resources to focus on key near-term value drivers and to extend its cash runway into the third quarter of 2024, supporting the execution of important clinical and preclinical milestones.